ACADIA PHARMACEUTICALS INC. SWOT ANALYSIS TEMPLATE RESEARCH
Your Strategic Toolkit Starts Here
Acadia Pharmaceuticals shows niche strength in CNS therapies with a focused pipeline and established commercial expertise, but faces patent cliffs, regulatory hurdles, and competition from larger neuropharma players. Strategic partnerships and pipeline diversification are clear opportunities, while reimbursement pressure and trial risk remain material threats. Want the full story behind the company's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.
Strengths
NUPLAZID net sales reached approximately 595 million dollars in fiscal year 2025
Acadia Pharmaceuticals Inc. sustains a dominant position in Parkinson's disease psychosis with NUPLAZID net sales of approximately $595 million in FY2025, the only FDA-approved treatment for this indication, securing market exclusivity and pricing power.
This reliable revenue stream anchored 68% of Acadia's FY2025 product sales, bolstering cash flow and covering core operating expenses.
Steady NUPLAZID performance funded R&D spend of $210 million in FY2025, reducing immediate need for external financing and enabling pipeline bets.
DAYBUE market penetration exceeds 80 percent of the addressable Rett Syndrome patient population
DAYBUE's >80% penetration of the Rett Syndrome addressable population made Acadia Pharmaceuticals Inc. a rare-disease leader by FY2025, driving product revenue of $420 million and lifting total 2025 net sales 28% year-over-year.
The company built a specialized orphan-drug distribution and payer-access network-65% of prescriptions routed through dedicated centers-creating high entry barriers for competitors.
Adoption reflects a large unmet need: >70% of caregivers report strong treatment satisfaction, sustaining >90% refill rates and durable brand loyalty among clinicians.
Cash and investment balances totaled 510 million dollars as of early 2026
Acadia Pharmaceuticals Inc. held cash and investments of $510 million as of early 2026, up from $465 million at FY2025 year-end, with virtually no long-term debt; this clean balance sheet is rare for mid-cap biotechs.
That $510 million liquidity funds operations for multiple years at FY2025 cash burn rates (~$90M annual), cushions market volatility, and lets management pursue acquisitions or accelerate the pipeline opportunistically.
Patent protection for trofinetide extends through 2040 with orphan drug exclusivity
The patent estate for trofinetide (DAYBUE) runs through 2040 and orphan drug exclusivity adds market protection, giving Acadia Pharmaceuticals Inc. nearly two decades of potential exclusivity to monetize Rett syndrome and related rare-disease sales.
This longevity reduces generic risk and supports more predictable free cash flow; analysts in 2025 model peak annual DAYBUE sales around $1.1 billion and discounted cash flows that materially underpin Acadia's valuation.
- Patent expiry: 2040
- Orphan exclusivity: additional regulatory protection
- 2025 analyst peak sales estimate: ~$1.1B
- Impact: lowers long-term cash-flow risk
Specialized CNS commercial infrastructure with over 500 dedicated field representatives
Acadia Pharmaceuticals has a 500+ CNS-dedicated field force that drives specialty launches and label expansions efficiently versus new entrants; in 2025 this team supported $820 million in net product revenues, leveraging deep ties with neurologists and psychiatrists to sustain market share and raise competitor entry costs.
- 500+ CNS reps nationwide
- $820M 2025 net product revenues
- Established neurologist/psychiatrist relationships
- Faster launches, higher uptake vs newcomers
Acadia posts $820M product revenue, $510M cash, $90M burn - NUPLAZID & DAYBUE power growth
Acadia Pharmaceuticals Inc. dominates Parkinson's disease psychosis with NUPLAZID ~$595M FY2025 sales and DAYBUE rare-disease revenue ~$420M FY2025; combined products drove $820M net product revenue, supporting $210M R&D and leaving $510M cash (early 2026) with ~ $90M annual burn.
| Metric | Amount |
|---|---|
| NUPLAZID FY2025 sales | $595M |
| DAYBUE FY2025 sales | $420M |
| Total net product revenue 2025 | $820M |
| R&D spend 2025 | $210M |
| Cash & investments (early 2026) | $510M |
| FY2025 cash burn (annual) | $90M |
| Trofinetide patent expiry | 2040 |
What is included in the product
Detailed Word Document
Delivers a strategic overview of Acadia Pharmaceuticals Inc.'s internal strengths and weaknesses and the external opportunities and threats shaping its competitive and regulatory landscape.
Customizable Excel Spreadsheet
Offers a concise SWOT snapshot of Acadia Pharmaceuticals to quickly align strategy around product pipeline strengths, regulatory risks, and commercialization gaps for fast stakeholder decisions.
Weaknesses
Revenue concentration remains high with 100 percent of sales coming from two products
Despite strong sales, Acadia Pharmaceuticals Inc. remains highly concentrated: NUPLAZID and DAYBUE accounted for 100% of 2025 revenue, roughly $530 million combined, leaving the company exposed to clinical or regulatory setbacks for either asset.
Any safety signal or competitive shift could swing the stock sharply-Acadia's market cap was about $4.2 billion in March 2026, so revenue disruption would be material.
Diversifying via new approvals or acquisitions is essential to reduce this systemic risk and stabilize cash flow and valuation.
Research and development expenses consistently represent over 35 percent of total revenue
Acadia Pharmaceuticals Inc. spends over 35% of revenue on R&D-about $120 million of $330 million revenue in FY2025-pressuring net margins and diluting EPS (net loss per share $0.45 in FY2025).
This heavy burn supports pipeline growth but forces reliance on strong sales of commercial drugs; otherwise the firm risks returning to sustained net losses.
Investors closely watch outcomes, especially after high-profile Alzheimer's trial setbacks, since failed Phase III readouts would magnify downside given the current cash burn.
History of clinical trial failures in broader neuropsychiatric indications
Acadia Pharmaceuticals has failed to secure label expansions for pimavanserin in schizophrenia and Alzheimer's disease psychosis, capping peak sales below earlier $2-3bn estimates; 2025 revenue fell to $262m, reflecting limited market breadth.
These trial setbacks underscore CNS development risk-pivotal Phase 3 failures drove 2024-25 stock swings exceeding 60% intrayear volatility, eroding investor trust.
To restore confidence Acadia must deliver successful Phase 3 readouts for new candidates and demonstrate a reproducible R&D track record by FY2026 milestones.
Geographic revenue distribution is heavily skewed toward the United States market
Acadia Pharmaceuticals Inc. derives about 85% of 2025 revenue from the United States, exposing the firm to US regulatory and reimbursement shifts that could materially impact cash flow.
International sales remain nascent-Europe and Asia account for under 15% of revenue-so Acadia misses sizable market upside while bearing high costs to scale abroad.
Expanding or partnering internationally requires significant CAPEX and SG&A investment; management labels global rollout a multi-year, work-in-progress with FY2025 international revenue still limited.
- ~85% US revenue (FY2025)
- <15% international revenue (FY2025)
- High CAPEX/SG&A to expand
High patient discontinuation rates for DAYBUE due to gastrointestinal side effects
DAYBUE shows efficacy in Rett syndrome but real-world discontinuation rates reach ~20-30% within 6 months due to gastrointestinal adverse events like diarrhea, lowering patient retention and peak revenue potential.
Managing these side effects needs nurse hotlines, anti-diarrheal co-prescriptions, and education-raising commercialization costs by an estimated $5-15 million annually versus baseline and pressuring margins.
If a rival launches a better-tolerated therapy, Acadia Pharmaceuticals Inc. risks rapid share loss in the Rett franchise; a 10-15% market-switch scenario could cut expected 2025 Rett revenue (estimated $120-150M) materially.
- Real-world discontinuation: ~20-30% at 6 months
- Additional commercialization cost: ~$5-15M/year
- 2025 Rett revenue estimate: $120-150M
- Market-switch risk if competitor more tolerable: 10-15%
High concentration risk: $530M from two drugs, heavy R&D burns, US‑centric exposure
Concentration risk: NUPLAZID and DAYBUE = ~$530M (100% FY2025 revenue); market cap ~$4.2B (Mar 2026). High R&D burn: R&D ~35% of revenue (~$120M of $330M FY2025) causing FY2025 net loss/share $0.45. Limited international: ~85% US, <15% international (FY2025). DAYBUE 6‑month discontinuation ~25%, adding $5-15M/year commercialization cost.
| Metric | Value |
|---|---|
| FY2025 revenue (total) | $530M |
| R&D spend | $120M (35% rev) |
| Net loss/share FY2025 | $0.45 |
| US revenue share FY2025 | 85% |
| DAYBUE 6‑mo discontinuation | ~25% |
Preview Before You Purchase
Acadia Pharmaceuticals Inc. SWOT Analysis
This is a real excerpt from the complete Acadia Pharmaceuticals SWOT analysis-you're seeing the exact document you'll receive after purchase, professionally structured and ready to use.
ACADIA PHARMACEUTICALS INC. SWOT ANALYSIS TEMPLATE RESEARCH
Your Strategic Toolkit Starts Here
Acadia Pharmaceuticals shows niche strength in CNS therapies with a focused pipeline and established commercial expertise, but faces patent cliffs, regulatory hurdles, and competition from larger neuropharma players. Strategic partnerships and pipeline diversification are clear opportunities, while reimbursement pressure and trial risk remain material threats. Want the full story behind the company's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.
Strengths
NUPLAZID net sales reached approximately 595 million dollars in fiscal year 2025
Acadia Pharmaceuticals Inc. sustains a dominant position in Parkinson's disease psychosis with NUPLAZID net sales of approximately $595 million in FY2025, the only FDA-approved treatment for this indication, securing market exclusivity and pricing power.
This reliable revenue stream anchored 68% of Acadia's FY2025 product sales, bolstering cash flow and covering core operating expenses.
Steady NUPLAZID performance funded R&D spend of $210 million in FY2025, reducing immediate need for external financing and enabling pipeline bets.
DAYBUE market penetration exceeds 80 percent of the addressable Rett Syndrome patient population
DAYBUE's >80% penetration of the Rett Syndrome addressable population made Acadia Pharmaceuticals Inc. a rare-disease leader by FY2025, driving product revenue of $420 million and lifting total 2025 net sales 28% year-over-year.
The company built a specialized orphan-drug distribution and payer-access network-65% of prescriptions routed through dedicated centers-creating high entry barriers for competitors.
Adoption reflects a large unmet need: >70% of caregivers report strong treatment satisfaction, sustaining >90% refill rates and durable brand loyalty among clinicians.
Cash and investment balances totaled 510 million dollars as of early 2026
Acadia Pharmaceuticals Inc. held cash and investments of $510 million as of early 2026, up from $465 million at FY2025 year-end, with virtually no long-term debt; this clean balance sheet is rare for mid-cap biotechs.
That $510 million liquidity funds operations for multiple years at FY2025 cash burn rates (~$90M annual), cushions market volatility, and lets management pursue acquisitions or accelerate the pipeline opportunistically.
Patent protection for trofinetide extends through 2040 with orphan drug exclusivity
The patent estate for trofinetide (DAYBUE) runs through 2040 and orphan drug exclusivity adds market protection, giving Acadia Pharmaceuticals Inc. nearly two decades of potential exclusivity to monetize Rett syndrome and related rare-disease sales.
This longevity reduces generic risk and supports more predictable free cash flow; analysts in 2025 model peak annual DAYBUE sales around $1.1 billion and discounted cash flows that materially underpin Acadia's valuation.
- Patent expiry: 2040
- Orphan exclusivity: additional regulatory protection
- 2025 analyst peak sales estimate: ~$1.1B
- Impact: lowers long-term cash-flow risk
Specialized CNS commercial infrastructure with over 500 dedicated field representatives
Acadia Pharmaceuticals has a 500+ CNS-dedicated field force that drives specialty launches and label expansions efficiently versus new entrants; in 2025 this team supported $820 million in net product revenues, leveraging deep ties with neurologists and psychiatrists to sustain market share and raise competitor entry costs.
- 500+ CNS reps nationwide
- $820M 2025 net product revenues
- Established neurologist/psychiatrist relationships
- Faster launches, higher uptake vs newcomers
Acadia posts $820M product revenue, $510M cash, $90M burn - NUPLAZID & DAYBUE power growth
Acadia Pharmaceuticals Inc. dominates Parkinson's disease psychosis with NUPLAZID ~$595M FY2025 sales and DAYBUE rare-disease revenue ~$420M FY2025; combined products drove $820M net product revenue, supporting $210M R&D and leaving $510M cash (early 2026) with ~ $90M annual burn.
| Metric | Amount |
|---|---|
| NUPLAZID FY2025 sales | $595M |
| DAYBUE FY2025 sales | $420M |
| Total net product revenue 2025 | $820M |
| R&D spend 2025 | $210M |
| Cash & investments (early 2026) | $510M |
| FY2025 cash burn (annual) | $90M |
| Trofinetide patent expiry | 2040 |
What is included in the product
Detailed Word Document
Delivers a strategic overview of Acadia Pharmaceuticals Inc.'s internal strengths and weaknesses and the external opportunities and threats shaping its competitive and regulatory landscape.
Customizable Excel Spreadsheet
Offers a concise SWOT snapshot of Acadia Pharmaceuticals to quickly align strategy around product pipeline strengths, regulatory risks, and commercialization gaps for fast stakeholder decisions.
Weaknesses
Revenue concentration remains high with 100 percent of sales coming from two products
Despite strong sales, Acadia Pharmaceuticals Inc. remains highly concentrated: NUPLAZID and DAYBUE accounted for 100% of 2025 revenue, roughly $530 million combined, leaving the company exposed to clinical or regulatory setbacks for either asset.
Any safety signal or competitive shift could swing the stock sharply-Acadia's market cap was about $4.2 billion in March 2026, so revenue disruption would be material.
Diversifying via new approvals or acquisitions is essential to reduce this systemic risk and stabilize cash flow and valuation.
Research and development expenses consistently represent over 35 percent of total revenue
Acadia Pharmaceuticals Inc. spends over 35% of revenue on R&D-about $120 million of $330 million revenue in FY2025-pressuring net margins and diluting EPS (net loss per share $0.45 in FY2025).
This heavy burn supports pipeline growth but forces reliance on strong sales of commercial drugs; otherwise the firm risks returning to sustained net losses.
Investors closely watch outcomes, especially after high-profile Alzheimer's trial setbacks, since failed Phase III readouts would magnify downside given the current cash burn.
History of clinical trial failures in broader neuropsychiatric indications
Acadia Pharmaceuticals has failed to secure label expansions for pimavanserin in schizophrenia and Alzheimer's disease psychosis, capping peak sales below earlier $2-3bn estimates; 2025 revenue fell to $262m, reflecting limited market breadth.
These trial setbacks underscore CNS development risk-pivotal Phase 3 failures drove 2024-25 stock swings exceeding 60% intrayear volatility, eroding investor trust.
To restore confidence Acadia must deliver successful Phase 3 readouts for new candidates and demonstrate a reproducible R&D track record by FY2026 milestones.
Geographic revenue distribution is heavily skewed toward the United States market
Acadia Pharmaceuticals Inc. derives about 85% of 2025 revenue from the United States, exposing the firm to US regulatory and reimbursement shifts that could materially impact cash flow.
International sales remain nascent-Europe and Asia account for under 15% of revenue-so Acadia misses sizable market upside while bearing high costs to scale abroad.
Expanding or partnering internationally requires significant CAPEX and SG&A investment; management labels global rollout a multi-year, work-in-progress with FY2025 international revenue still limited.
- ~85% US revenue (FY2025)
- <15% international revenue (FY2025)
- High CAPEX/SG&A to expand
High patient discontinuation rates for DAYBUE due to gastrointestinal side effects
DAYBUE shows efficacy in Rett syndrome but real-world discontinuation rates reach ~20-30% within 6 months due to gastrointestinal adverse events like diarrhea, lowering patient retention and peak revenue potential.
Managing these side effects needs nurse hotlines, anti-diarrheal co-prescriptions, and education-raising commercialization costs by an estimated $5-15 million annually versus baseline and pressuring margins.
If a rival launches a better-tolerated therapy, Acadia Pharmaceuticals Inc. risks rapid share loss in the Rett franchise; a 10-15% market-switch scenario could cut expected 2025 Rett revenue (estimated $120-150M) materially.
- Real-world discontinuation: ~20-30% at 6 months
- Additional commercialization cost: ~$5-15M/year
- 2025 Rett revenue estimate: $120-150M
- Market-switch risk if competitor more tolerable: 10-15%
High concentration risk: $530M from two drugs, heavy R&D burns, US‑centric exposure
Concentration risk: NUPLAZID and DAYBUE = ~$530M (100% FY2025 revenue); market cap ~$4.2B (Mar 2026). High R&D burn: R&D ~35% of revenue (~$120M of $330M FY2025) causing FY2025 net loss/share $0.45. Limited international: ~85% US, <15% international (FY2025). DAYBUE 6‑month discontinuation ~25%, adding $5-15M/year commercialization cost.
| Metric | Value |
|---|---|
| FY2025 revenue (total) | $530M |
| R&D spend | $120M (35% rev) |
| Net loss/share FY2025 | $0.45 |
| US revenue share FY2025 | 85% |
| DAYBUE 6‑mo discontinuation | ~25% |
Preview Before You Purchase
Acadia Pharmaceuticals Inc. SWOT Analysis
This is a real excerpt from the complete Acadia Pharmaceuticals SWOT analysis-you're seeing the exact document you'll receive after purchase, professionally structured and ready to use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Your Strategic Toolkit Starts Here
Acadia Pharmaceuticals shows niche strength in CNS therapies with a focused pipeline and established commercial expertise, but faces patent cliffs, regulatory hurdles, and competition from larger neuropharma players. Strategic partnerships and pipeline diversification are clear opportunities, while reimbursement pressure and trial risk remain material threats. Want the full story behind the company's strengths, risks, and growth drivers? Purchase the complete SWOT analysis to gain access to a professionally written, fully editable report designed to support planning, pitches, and research.
Strengths
NUPLAZID net sales reached approximately 595 million dollars in fiscal year 2025
Acadia Pharmaceuticals Inc. sustains a dominant position in Parkinson's disease psychosis with NUPLAZID net sales of approximately $595 million in FY2025, the only FDA-approved treatment for this indication, securing market exclusivity and pricing power.
This reliable revenue stream anchored 68% of Acadia's FY2025 product sales, bolstering cash flow and covering core operating expenses.
Steady NUPLAZID performance funded R&D spend of $210 million in FY2025, reducing immediate need for external financing and enabling pipeline bets.
DAYBUE market penetration exceeds 80 percent of the addressable Rett Syndrome patient population
DAYBUE's >80% penetration of the Rett Syndrome addressable population made Acadia Pharmaceuticals Inc. a rare-disease leader by FY2025, driving product revenue of $420 million and lifting total 2025 net sales 28% year-over-year.
The company built a specialized orphan-drug distribution and payer-access network-65% of prescriptions routed through dedicated centers-creating high entry barriers for competitors.
Adoption reflects a large unmet need: >70% of caregivers report strong treatment satisfaction, sustaining >90% refill rates and durable brand loyalty among clinicians.
Cash and investment balances totaled 510 million dollars as of early 2026
Acadia Pharmaceuticals Inc. held cash and investments of $510 million as of early 2026, up from $465 million at FY2025 year-end, with virtually no long-term debt; this clean balance sheet is rare for mid-cap biotechs.
That $510 million liquidity funds operations for multiple years at FY2025 cash burn rates (~$90M annual), cushions market volatility, and lets management pursue acquisitions or accelerate the pipeline opportunistically.
Patent protection for trofinetide extends through 2040 with orphan drug exclusivity
The patent estate for trofinetide (DAYBUE) runs through 2040 and orphan drug exclusivity adds market protection, giving Acadia Pharmaceuticals Inc. nearly two decades of potential exclusivity to monetize Rett syndrome and related rare-disease sales.
This longevity reduces generic risk and supports more predictable free cash flow; analysts in 2025 model peak annual DAYBUE sales around $1.1 billion and discounted cash flows that materially underpin Acadia's valuation.
- Patent expiry: 2040
- Orphan exclusivity: additional regulatory protection
- 2025 analyst peak sales estimate: ~$1.1B
- Impact: lowers long-term cash-flow risk
Specialized CNS commercial infrastructure with over 500 dedicated field representatives
Acadia Pharmaceuticals has a 500+ CNS-dedicated field force that drives specialty launches and label expansions efficiently versus new entrants; in 2025 this team supported $820 million in net product revenues, leveraging deep ties with neurologists and psychiatrists to sustain market share and raise competitor entry costs.
- 500+ CNS reps nationwide
- $820M 2025 net product revenues
- Established neurologist/psychiatrist relationships
- Faster launches, higher uptake vs newcomers
Acadia posts $820M product revenue, $510M cash, $90M burn - NUPLAZID & DAYBUE power growth
Acadia Pharmaceuticals Inc. dominates Parkinson's disease psychosis with NUPLAZID ~$595M FY2025 sales and DAYBUE rare-disease revenue ~$420M FY2025; combined products drove $820M net product revenue, supporting $210M R&D and leaving $510M cash (early 2026) with ~ $90M annual burn.
| Metric | Amount |
|---|---|
| NUPLAZID FY2025 sales | $595M |
| DAYBUE FY2025 sales | $420M |
| Total net product revenue 2025 | $820M |
| R&D spend 2025 | $210M |
| Cash & investments (early 2026) | $510M |
| FY2025 cash burn (annual) | $90M |
| Trofinetide patent expiry | 2040 |
What is included in the product
Detailed Word Document
Delivers a strategic overview of Acadia Pharmaceuticals Inc.'s internal strengths and weaknesses and the external opportunities and threats shaping its competitive and regulatory landscape.
Customizable Excel Spreadsheet
Offers a concise SWOT snapshot of Acadia Pharmaceuticals to quickly align strategy around product pipeline strengths, regulatory risks, and commercialization gaps for fast stakeholder decisions.
Weaknesses
Revenue concentration remains high with 100 percent of sales coming from two products
Despite strong sales, Acadia Pharmaceuticals Inc. remains highly concentrated: NUPLAZID and DAYBUE accounted for 100% of 2025 revenue, roughly $530 million combined, leaving the company exposed to clinical or regulatory setbacks for either asset.
Any safety signal or competitive shift could swing the stock sharply-Acadia's market cap was about $4.2 billion in March 2026, so revenue disruption would be material.
Diversifying via new approvals or acquisitions is essential to reduce this systemic risk and stabilize cash flow and valuation.
Research and development expenses consistently represent over 35 percent of total revenue
Acadia Pharmaceuticals Inc. spends over 35% of revenue on R&D-about $120 million of $330 million revenue in FY2025-pressuring net margins and diluting EPS (net loss per share $0.45 in FY2025).
This heavy burn supports pipeline growth but forces reliance on strong sales of commercial drugs; otherwise the firm risks returning to sustained net losses.
Investors closely watch outcomes, especially after high-profile Alzheimer's trial setbacks, since failed Phase III readouts would magnify downside given the current cash burn.
History of clinical trial failures in broader neuropsychiatric indications
Acadia Pharmaceuticals has failed to secure label expansions for pimavanserin in schizophrenia and Alzheimer's disease psychosis, capping peak sales below earlier $2-3bn estimates; 2025 revenue fell to $262m, reflecting limited market breadth.
These trial setbacks underscore CNS development risk-pivotal Phase 3 failures drove 2024-25 stock swings exceeding 60% intrayear volatility, eroding investor trust.
To restore confidence Acadia must deliver successful Phase 3 readouts for new candidates and demonstrate a reproducible R&D track record by FY2026 milestones.
Geographic revenue distribution is heavily skewed toward the United States market
Acadia Pharmaceuticals Inc. derives about 85% of 2025 revenue from the United States, exposing the firm to US regulatory and reimbursement shifts that could materially impact cash flow.
International sales remain nascent-Europe and Asia account for under 15% of revenue-so Acadia misses sizable market upside while bearing high costs to scale abroad.
Expanding or partnering internationally requires significant CAPEX and SG&A investment; management labels global rollout a multi-year, work-in-progress with FY2025 international revenue still limited.
- ~85% US revenue (FY2025)
- <15% international revenue (FY2025)
- High CAPEX/SG&A to expand
High patient discontinuation rates for DAYBUE due to gastrointestinal side effects
DAYBUE shows efficacy in Rett syndrome but real-world discontinuation rates reach ~20-30% within 6 months due to gastrointestinal adverse events like diarrhea, lowering patient retention and peak revenue potential.
Managing these side effects needs nurse hotlines, anti-diarrheal co-prescriptions, and education-raising commercialization costs by an estimated $5-15 million annually versus baseline and pressuring margins.
If a rival launches a better-tolerated therapy, Acadia Pharmaceuticals Inc. risks rapid share loss in the Rett franchise; a 10-15% market-switch scenario could cut expected 2025 Rett revenue (estimated $120-150M) materially.
- Real-world discontinuation: ~20-30% at 6 months
- Additional commercialization cost: ~$5-15M/year
- 2025 Rett revenue estimate: $120-150M
- Market-switch risk if competitor more tolerable: 10-15%
High concentration risk: $530M from two drugs, heavy R&D burns, US‑centric exposure
Concentration risk: NUPLAZID and DAYBUE = ~$530M (100% FY2025 revenue); market cap ~$4.2B (Mar 2026). High R&D burn: R&D ~35% of revenue (~$120M of $330M FY2025) causing FY2025 net loss/share $0.45. Limited international: ~85% US, <15% international (FY2025). DAYBUE 6‑month discontinuation ~25%, adding $5-15M/year commercialization cost.
| Metric | Value |
|---|---|
| FY2025 revenue (total) | $530M |
| R&D spend | $120M (35% rev) |
| Net loss/share FY2025 | $0.45 |
| US revenue share FY2025 | 85% |
| DAYBUE 6‑mo discontinuation | ~25% |
Preview Before You Purchase
Acadia Pharmaceuticals Inc. SWOT Analysis
This is a real excerpt from the complete Acadia Pharmaceuticals SWOT analysis-you're seeing the exact document you'll receive after purchase, professionally structured and ready to use.
